BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28823644)

  • 1. 9-Phenanthrol enhances the generation of an CD8
    Hartmann AK; Aranda Lopez P; Zajac M; Freichel M; Schild H; Radsak MP; Stassen M
    J Dermatol Sci; 2017 Sep; 87(3):260-267. PubMed ID: 28823644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protection.
    Lopez PA; Denny M; Hartmann AK; Alflen A; Probst HC; von Stebut E; Tenzer S; Schild H; Stassen M; Langguth P; Radsak MP
    J Dermatol Sci; 2017 Sep; 87(3):252-259. PubMed ID: 28655469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of imiquimod-based transcutaneous immunization using a nano-dispersed emulsion gel formulation.
    Stein P; Gogoll K; Tenzer S; Schild H; Stevanovic S; Langguth P; Radsak MP
    PLoS One; 2014; 9(7):e102664. PubMed ID: 25025233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
    Rausch J; Lopez PA; Bialojan A; Denny M; Langguth P; Probst HC; Schild H; Radsak MP
    J Dermatol Sci; 2017 Sep; 87(3):300-306. PubMed ID: 28666747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcutaneous immunization with CD40 ligation boosts cytotoxic T lymphocyte mediated antitumor immunity independent of CD4 helper cells in mice.
    Bialojan A; Sohl J; Rausch J; Aranda Lopez P; Denny M; Langguth P; Hartmann AK; Yagita H; Probst HC; Schild H; Radsak MP
    Eur J Immunol; 2019 Nov; 49(11):2083-2094. PubMed ID: 31393597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mast cells are crucial for early inflammation, migration of Langerhans cells, and CTL responses following topical application of TLR7 ligand in mice.
    Heib V; Becker M; Warger T; Rechtsteiner G; Tertilt C; Klein M; Bopp T; Taube C; Schild H; Schmitt E; Stassen M
    Blood; 2007 Aug; 110(3):946-53. PubMed ID: 17446350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solid nanoemulsion as antigen and immunopotentiator carrier for transcutaneous immunization.
    Gogoll K; Stein P; Lee KD; Arnold P; Peters T; Schild H; Radsak M; Langguth P
    Cell Immunol; 2016 Oct; 308():35-43. PubMed ID: 27318760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection.
    Warger T; Rechtsteiner G; Schmid B; Osterloh P; Schild H; Radsak MP
    Clin Rev Allergy Immunol; 2007 Feb; 32(1):57-66. PubMed ID: 17426361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UV exposure boosts transcutaneous immunization and improves tumor immunity: cytotoxic T-cell priming through the skin.
    Stein P; Rechtsteiner G; Warger T; Bopp T; Fuhr T; Prüfer S; Probst HC; Stassen M; Langguth P; Schild H; Radsak MP
    J Invest Dermatol; 2011 Jan; 131(1):211-9. PubMed ID: 20739947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory T cells and IL-10 independently counterregulate cytotoxic T lymphocyte responses induced by transcutaneous immunization.
    Stein P; Weber M; Prüfer S; Schmid B; Schmitt E; Probst HC; Waisman A; Langguth P; Schild H; Radsak MP
    PLoS One; 2011; 6(11):e27911. PubMed ID: 22114725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity.
    Prins RM; Craft N; Bruhn KW; Khan-Farooqi H; Koya RC; Stripecke R; Miller JF; Liau LM
    J Immunol; 2006 Jan; 176(1):157-64. PubMed ID: 16365406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimized dithranol-imiquimod-based transcutaneous immunization enables tumor rejection.
    Hartmann AK; Bartneck J; Pielenhofer J; Meiser SL; Arnold-Schild D; Klein M; Stassen M; Schild H; Muth S; Probst HC; Langguth P; Grabbe S; Radsak MP
    Front Immunol; 2023; 14():1238861. PubMed ID: 37727790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming.
    Fehres CM; Bruijns SC; van Beelen AJ; Kalay H; Ambrosini M; Hooijberg E; Unger WW; de Gruijl TD; van Kooyk Y
    Eur J Immunol; 2014 Aug; 44(8):2415-24. PubMed ID: 24825342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod.
    Rechtsteiner G; Warger T; Osterloh P; Schild H; Radsak MP
    J Immunol; 2005 Mar; 174(5):2476-80. PubMed ID: 15728450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A short hairpin RNA-based adjuvant targeting NF-κB repressor IκBα promotes migration of dermal dendritic cells to draining lymph nodes and antitumor CTL responses induced by DNA vaccination.
    Gálvez-Cancino F; Roco J; Rojas-Colonelli N; Flores C; Murgas P; Cruz-Gómez S; Oyarce C; Varas-Godoy M; Sauma D; Lladser A
    Vaccine; 2017 Jul; 35(33):4148-4154. PubMed ID: 28666759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New perspective in immunotherapy: local imiquimod treatment].
    Kemény L; Nagy N
    Orv Hetil; 2010 May; 151(19):774-83. PubMed ID: 20427260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors.
    Xiong Z; Ohlfest JR
    J Immunother; 2011 Apr; 34(3):264-9. PubMed ID: 21389872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Memory Th1 cells augment tumor-specific CTL following transcutaneous peptide immunization.
    Hosoi A; Takeda Y; Furuichi Y; Kurachi M; Kimura K; Maekawa R; Takatsu K; Kakimi K
    Cancer Res; 2008 May; 68(10):3941-9. PubMed ID: 18483280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
    Sun JB; Eriksson K; Li BL; Lindblad M; Azem J; Holmgren J
    Clin Immunol; 2004 Jul; 112(1):35-44. PubMed ID: 15207780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcutaneous immunization in mice: induction of T-helper and cytotoxic T lymphocyte responses and protection against human papillomavirus-induced tumors.
    Dell K; Koesters R; Gissmann L
    Int J Cancer; 2006 Jan; 118(2):364-72. PubMed ID: 16052529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.